All Stories

  1. Non‐bacterial thrombotic endocarditis in a patient with pancreatic carcinoma

    Article • Echocardiography, July 2021, Wiley

    Professor Thomas Munzel or Muenzel, PD Dr. Arndt Weinmann

  2. The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma

    Article • Journal of Clinical Medicine, June 2021, MDPI AG

    PD Dr. Arndt Weinmann

  3. Patterns of liver injury in COVID-19 – a German case series

    Article • United European Gastroenterology Journal, June 2020, SAGE Publications

    PD Dr. Arndt Weinmann

  4. Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging

    Article • Journal of Cancer Research and Clinical Oncology, March 2020, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  5. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

    Article • Clinical Gastroenterology and Hepatology, March 2020, Elsevier

    PD Dr. Arndt Weinmann

  6. P125 Internet-based exercise therapy in patients with systemic lupus erythematodes – systemic lupus erythematodes exercise program (SLEEP)

    Article • March 2020, BMJ

    PD Dr. Arndt Weinmann

  7. Risk prediction in intrahepatic cholangiocarcinoma: Direct comparison of the MEGNA score and the 8th edition of the UICC/AJCC Cancer staging system

    Article • PLoS ONE, February 2020, PLOS

    Arndt Weinmann, PD Dr. Arndt Weinmann

  8. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients

    Article • United European Gastroenterology Journal, January 2020, SAGE Publications

    PD Dr. Arndt Weinmann

  9. Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study

    Article • Liver International, January 2020, Wiley

    Arndt Weinmann, PD Dr. Arndt Weinmann

  10. Monozentrische Erfahrungen mit stereotaktischer Bestrahlung (SBRT) beim fortgeschrittenen hepatozellulären Karzinom im Stadium BCLC-C

    Article • Zeitschrift für Gastroenterologie, January 2020, Thieme Publishing Group

    PD Dr. Arndt Weinmann

  11. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

    Article • American Journal of Transplantation, September 2019, Wiley

    PD Dr. Arndt Weinmann

  12. Fatigue in SLE: diagnostic and pathogenic impact of anti-N-methyl-D-aspartate receptor (NMDAR) autoantibodies

    Article • Annals of the Rheumatic Diseases, June 2019, BMJ

    PD Dr. Arndt Weinmann

  13. The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?

    Article • Liver International, May 2019, Wiley

    PD Dr. Arndt Weinmann

  14. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort

    Article • Alimentary Pharmacology & Therapeutics, April 2019, Wiley

    PD Dr. Arndt Weinmann

  15. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre

    Article • United European Gastroenterology Journal, March 2019, SAGE Publications

    PD Dr. Arndt Weinmann

  16. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma

    Article • Liver International, February 2019, Wiley

    PD Dr. Arndt Weinmann

  17. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

    Article • BMC Cancer, January 2019, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  18. Application of patient‐derived liver cancer cells for phenotypic characterization and therapeutic target identification

    Article • International Journal of Cancer, December 2018, Wiley

    PD Dr. Arndt Weinmann

  19. Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?

    Article • Liver International, November 2018, Wiley

    PD Dr. Arndt Weinmann

  20. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers

    Article • Journal of Cancer Research and Clinical Oncology, October 2018, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  21. Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma

    Article • Liver Cancer, October 2018, Karger Publishers

    PD Dr. Arndt Weinmann

  22. Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC

    Article • European Journal of Internal Medicine, September 2018, Elsevier

    PD Dr. Arndt Weinmann

  23. Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort

    Article • BMC Cancer, July 2018, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  24. Hepatorenales Syndrom

    Article • Der Nephrologe, June 2018, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  25. Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

    Article • BMC Cancer, April 2018, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  26. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial

    Article • Journal of Clinical Oncology, October 2017, American Society of Clinical Oncology (ASCO)

    PD Dr. Arndt Weinmann

  27. Risk estimation for biliary tract cancer: Development and validation of a prognostic score

    Article • Liver International, July 2017, Wiley

    PD Dr. Arndt Weinmann

  28. Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

    Article • Digestive Diseases, July 2017, Karger Publishers

    PD Dr. Arndt Weinmann

  29. Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men

    Article • Lupus, June 2017, SAGE Publications

    PD Dr. Arndt Weinmann

  30. Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease

    Article • United European Gastroenterology Journal, June 2017, SAGE Publications

    PD Dr. Arndt Weinmann

  31. Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas

    Article • Oncotarget, March 2017, Impact Journals, LLC

    PD Dr. Arndt Weinmann

  32. Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma

    Article • United European Gastroenterology Journal, February 2017, SAGE Publications

    PD Dr. Arndt Weinmann

  33. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma

    Article • CardioVascular and Interventional Radiology, February 2017, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  34. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma

    Article • Journal of Vascular and Interventional Radiology, January 2017, Elsevier

    PD Dr. Arndt Weinmann

  35. Quantitative assessment of washout in hepatocellular carcinoma using MRI

    Article • BMC Cancer, September 2016, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  36. Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer

    Article • Gastric Cancer, June 2016, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  37. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

    Article • Clinical Gastroenterology and Hepatology, June 2016, Elsevier

    PD Dr. Arndt Weinmann

  38. Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment

    Article • BMC Cancer, February 2016, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  39. Stagewise pseudo-value regression for time-varying effects on the cumulative incidence

    Article • Statistics in Medicine, October 2015, Wiley

    PD Dr. Arndt Weinmann

  40. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma

    Article • BMC Cancer, June 2015, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  41. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma

    Article • BMC Cancer, April 2015, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  42. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion

    Article • Journal of Hepatology, April 2015, Elsevier

    PD Dr. Arndt Weinmann

  43. Predictive Scores in Primary Biliary Cirrhosis

    Article • Journal of Clinical Gastroenterology, January 2015, Wolters Kluwer Health

    PD Dr. Arndt Weinmann

  44. Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma

    Article • CardioVascular and Interventional Radiology, November 2014, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  45. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients

    Article • Liver International, October 2014, Wiley

    PD Dr. Arndt Weinmann

  46. Coupled variable selection for regression modeling of complex treatment patterns in a clinical cancer registry

    Article • Statistics in Medicine, October 2014, Wiley

    PD Dr. Arndt Weinmann

  47. Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial

    Article • Journal of Experimental & Clinical Cancer Research, October 2014, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  48. Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!

    Article • Journal of Cancer Research and Clinical Oncology, September 2014, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  49. Ätiologie und Komplikationen der Leberzirrhose: Daten eines deutschen Zentrums

    Article • DMW - Deutsche Medizinische Wochenschrift, August 2014, Thieme Publishing Group

    Dr J. M. Schattenberg, PD Dr. Arndt Weinmann

  50. Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial

    Article • Trials, August 2014, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  51. Colony-Stimulating Factor-1: A Potential Biomarker for Lupus Nephritis

    Article • Journal of the American Society of Nephrology, July 2014, American Society of Nephrology

    PD Dr. Arndt Weinmann

  52. Trends in Epidemiology, Treatment, and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009

    Article • Journal of Clinical Gastroenterology, March 2014, Wolters Kluwer Health

    PD Dr. Arndt Weinmann

  53. Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents

    Article • Digestive and Liver Disease, January 2014, Elsevier

    PD Dr. Arndt Weinmann

  54. Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment

    Article • Journal of Viral Hepatitis, November 2013, Wiley

    PD Dr. Arndt Weinmann

  55. Therapie des hepatozellulären Karzinoms

    Article • Der Internist, November 2013, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  56. Diagnostik und Therapie des hepatozellulären Karzinoms

    Article • Seminars in Musculoskeletal Radiology, November 2013, Thieme Publishing Group

    PD Dr. Arndt Weinmann

  57. CellMinerHCC: a microarray-based expression database for hepatocellular carcinoma cell lines

    Article • Liver International, September 2013, Wiley

    PD Dr. Arndt Weinmann

  58. How to decide about liver transplantation in patients with hepatocellular carcinoma: Size and number of lesions or response to TACE?

    Article • Journal of Hepatology, August 2013, Elsevier

    PD Dr. Arndt Weinmann

  59. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma – A single-center experience

    Article • European Journal of Surgical Oncology, June 2013, Elsevier

    PD Dr. Arndt Weinmann

  60. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells

    Article • Hepatology, June 2013, Wiley

    PD Dr. Arndt Weinmann

  61. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib

    Article • Digestive and Liver Disease, May 2013, Elsevier

    PD Dr. Arndt Weinmann

  62. Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients

    Article • International Journal of Clinical Oncology, March 2013, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  63. Midterm follow-up after DC-BEAD™-TACE of Hepatocellular Carcinoma (HCC)

    Article • European Journal of Radiology, December 2012, Elsevier

    PD Dr. Arndt Weinmann

  64. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation

    Article • Transplant International, November 2012, Wiley

    PD Dr. Arndt Weinmann

  65. Clinicopathologic Features and Prognosis of Young Patients With Hepatocellular Carcinoma in a Large German Cohort

    Article • Journal of Clinical Gastroenterology, October 2012, Wolters Kluwer Health

    PD Dr. Arndt Weinmann

  66. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B

    Article • Journal of Clinical Virology, May 2012, Elsevier

    PD Dr. Arndt Weinmann

  67. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation

    Article • Digestive and Liver Disease, May 2012, Elsevier

    PD Dr. Arndt Weinmann

  68. Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver

    Article • Scandinavian Journal of Gastroenterology, April 2012, Taylor & Francis

    PD Dr. Arndt Weinmann

  69. AFP Measurement in Monitoring Treatment Response of Advanced Hepatocellular Carcinoma to Sorafenib: Case Report and Review of the Literature

    Article • Onkologie, January 2011, Karger Publishers

    PD Dr. Arndt Weinmann

  70. Concurrent Autoimmune Diseases in Patients With Autoimmune Hepatitis

    Article • Journal of Clinical Gastroenterology, March 2010, Wolters Kluwer Health

    PD Dr. Arndt Weinmann

  71. Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

    Article • Oncology, January 2010, Karger Publishers

    PD Dr. Arndt Weinmann

  72. Library of molecular associations: curating the complex molecular basis of liver diseases

    Article • BMC Genomics, January 2010, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  73. Novel ways to sensitise gastrointestinal cancer to apoptosis

    Article • Gut, June 2009, BMJ

    PD Dr. Arndt Weinmann

  74. Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

    Article • Journal of Clinical Gastroenterology, May 2009, Wolters Kluwer Health

    PD Dr. Arndt Weinmann

  75. Systemic Therapies in Hepatocellular Carcinoma

    Article • Digestive Diseases, January 2009, Karger Publishers

    PD Dr. Arndt Weinmann

  76. Hepatocellular carcinoma in patients with autoimmune hepatitis

    Article • World Journal of Gastroenterology, January 2009, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    PD Dr. Arndt Weinmann

  77. BlotBase: A northern blot database

    Article • Gene, December 2008, Elsevier

    PD Dr. Arndt Weinmann

  78. Hereditäre Lebererkrankungen

    Article • Gastroenterologie up2date, June 2007, Thieme Publishing Group

    PD Dr. Arndt Weinmann

  79. Genome-wide analysis of factors regulating gene expression in liver

    Article • Gene, March 2007, Elsevier

    PD Dr. Arndt Weinmann

  80. Genetics of hepatocellular carcinoma

    Article • World Journal of Gastroenterology, January 2007, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    PD Dr. Arndt Weinmann

  81. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction

    Article • BMC Cancer, October 2006, Springer Science + Business Media

    PD Dr. Arndt Weinmann

  82. Current bioinformatics tools in genomic biomedical research (Review)

    Article • International Journal of Molecular Medicine, June 2006, Spandidos Publications

    PD Dr. Arndt Weinmann

  83. Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients

    Article • World Journal of Gastroenterology, January 2006, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    PD Dr. Arndt Weinmann

  84. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy

    Article • Oncology Reports, January 2006, Spandidos Publications

    PD Dr. Arndt Weinmann

  85. Actin binding LIM protein 3 (abLIM3)

    Article • International Journal of Molecular Medicine, January 2006, Spandidos Publications

    PD Dr. Arndt Weinmann

  86. LASS6, an additional member of the longevity assurance gene family

    Article • International Journal of Molecular Medicine, November 2005, Spandidos Publications

    PD Dr. Arndt Weinmann

  87. In silico characterization of an Iroquois family-related homeodomain protein

    Article • International Journal of Molecular Medicine, September 2005, Spandidos Publications

    PD Dr. Arndt Weinmann

  88. In silico characterization of LZTS3, a potential tumor suppressor

    Article • Oncology Reports, August 2005, Spandidos Publications

    PD Dr. Arndt Weinmann

  89. Characterization of OEBT, a LIM protein

    Article • International Journal of Molecular Medicine, March 2005, Spandidos Publications

    PD Dr. Arndt Weinmann

  90. Stress protein/peptide complexes derived from autologous tumor tissue as tumor vaccines

    Article • Biochemical Pharmacology, November 1999, Elsevier

    PD Dr. Arndt Weinmann

  91. TAP-polymorphisms in juvenile onset psoriasis and psoriatic arthritis

    Article • Human Immunology, November 1996, Elsevier

    PD Dr. Arndt Weinmann